Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Toshihiko Agatsuma"'
Autor:
Ryota Ozawa, Kei Sonehara, Tsutomu Hachiya, Shuhei Nozawa, Toshihiko Agatsuma, Hiroshi Yamamoto, Akane Kato, Akemi Matsuo, Taro Hirabayashi, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Introduction Chemoimmunotherapy is widely used as the first‐line management of advanced non‐small cell lung cancer (NSCLC) in clinical settings. However, predictive factors associated with the development of immune‐related adverse even
Externí odkaz:
https://doaj.org/article/aa42099c35ad42f8a04023c3e61f282a
Autor:
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Background Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death‐ligand 1 (PD‐L1) expression is an important is
Externí odkaz:
https://doaj.org/article/9abe2da6e7c64c909348f0fdd32c3056
Autor:
Kai Morishita, Soichiro Kashiwabara, Yuki Matsumoto, Atsuhiro Mizushima, Kaori Hara, Toshihiko Agatsuma, Yuji Mimura, Hideyoshi Matsumura, Hiroya Mizusawa
Publikováno v:
Clinical Case Reports, Vol 12, Iss 1, Pp n/a-n/a (2024)
Key Clinical Message Even in a country where vancomycin–resistant enterococcus is rare, multidrug‐resistant organism precautions are necessary when admitting patients with a history of medical exposure in other countries. On admission, screening
Externí odkaz:
https://doaj.org/article/c52c376be2914ed68cb4d84eb63194b9
Autor:
Kei Sonehara, Ryota Ozawa, Mineyuki Hama, Shuhei Nozawa, Toshihiko Agatsuma, Kenichi Nishie, Akane Kato, Akemi Matsuo, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka
Publikováno v:
Thoracic Cancer, Vol 14, Iss 6, Pp 636-642 (2023)
Abstract Background Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first‐line treatment for advanced non‐small cell lung cancer (NSCLC). However, the therapeutic effect of combination im
Externí odkaz:
https://doaj.org/article/9497c8b11ed347c9b0b471268d489d91
Autor:
Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, Kei Sonehara, Satoshi Wasamoto, Shigeru Koyama, Fumiaki Yoshiike, Mineyuki Hama, Kenichi Nishie, Daichi Kondo, Toshihiko Agatsuma, Akane Kato, Munetake Takata, Shintaro Kanda, Masayuki Hanaoka, Tomonobu Koizumi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 14, Pp 2031-2040 (2022)
Abstract Backgrounds The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non–small cell lung cancer (LA‐NSCLC). However, little is known about the
Externí odkaz:
https://doaj.org/article/70885b62a3b64f34b89b53fcffcb92c5
Publikováno v:
Respiratory Medicine Case Reports, Vol 42, Iss , Pp 101817- (2023)
We report two cases of pulmonary collapse that simulated pneumothorax on computed tomographic images and were caused by rapid complete bronchial obstruction. One patient was a 77-year-old woman with sudden dyspnea, and the other was an 83-year-old wo
Externí odkaz:
https://doaj.org/article/6fdd65149b0e4b0eac9cfe172ee75b55
Autor:
Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz:
https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Autor:
Kei Sonehara, Ryota Ozawa, Mineyuki Hama, Shuhei Nozawa, Toshihiko Agatsuma, Kenichi Nishie, Akane Kato, Akemi Matsuo, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka
Publikováno v:
Thoracic Cancer. 14:636-642
Autor:
Takashi Kobayashi, Shintaro Kanda, Kazunari Tateishi, Nobutoshi Morozumi, Ryouhei Yamamoto, Fumiaki Yoshiike, Hideaki Takizawa, Munetaka Takada, Manabu Yamamoto, Kenichi Nishie, Takasuna Keiichiro, Toshihiko Agatsuma, Mineyuki Hama, Hozumi Tanaka, Akemi Matsuo, Akio Morikawa, Masayuki Hanaoka, Tomonobu Koizumi
Publikováno v:
Oncology in Clinical Practice (2450-1654); 2023, Vol. 19 Issue 5, p339-345, 7p
Autor:
Wataru Takahashi, Toshiko Mizuno, Kaori Hara, Yoshiaki Ara, Rikiya Hurutani, Toshihiko Agatsuma, Minoru Fujimori
Publikováno v:
Internal medicine (Tokyo, Japan). 61(21)
Objectives The influential factors for anti-severe acute respiratory syndrome coronavirus 2 spike protein antibody (S-ab) levels were assessed after the administration of BNT162b2 mRNA coronavirus disease-2019 (COVID-19) vaccine at short and medium t